Some applicants for a position who become an immediate or eventual disappointment after being hired, looked good on paper. Former associates and employer representatives who are contacted during the hiring process usually gloss things over or hesitate to say anything potentially damaging or revealing in order to avoid any possible legal repercussions.
Anything significant or monumental would be handled in a forthright manner and not as something surprisingly added to a meeting. I think that the prior CEO was possibly incompetent and unprofessional, and I am saying this while being professional and respectful to the company current management who are not interested in focusing on the past failures with unproductive negativity. Looking at news and actions in motion, I think accounting issues need to be addressed and clarified. Concerns from common sense nuts and bolts issues to a need of a visionary outlook are being put in place. Marketing is an issue and sales representatives' morale appears to be low in some instances and there is a great need of rebuilding confidence, so that employees have an allegiance to the company and are motivated to be productive. The tone is established at the top, but there was probably neglect, to say the least. All is well now and as well as it can be considering the situation and I am hoping that success in reviving profitability is achieved as soon as is possible.
THE POINT REVIEW
News and Insights
Exelixis, Inc. Could Soar to $8.00 in a Year: Analysts
By Danial Clarke - May 25, 2016
Exelixis, Inc. (NASDAQ:EXEL) shares traded +2.50% during the most recent session. Wall Street analysts covering the stock are projecting that the stock will reach $7.00 within the next 52-weeks. The mean target projections are based on 3 opinions, the mean target was last revised on 05/12/16. Since analyst price targets calculations are subjective, there often can be a wide range of targets from various analysts.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have high price target of $8.00 and with a conservative view have low price target of $5.00 with a standard deviation of $1.73. Standard deviation is a measure of the dispersion of a set of data from its mean. If seeing target price from optimistic overview then it has a 30 percent upside potential from the latest closing price of $6.15. This is the consensus price target based on the analysts polled by Thomson Reuters’ First Call, the average is taken from the individual analysts which provided targets and are short term projections for the 12 months.
This is the kind of guy who knows nothing about the stock market and will be dependent upon taxpayers for food stamps in a few years if he is not already.
Pernix Therapeutics Holdings, Inc.
Focus Stock Earnings and Rating Review
by Franklin Staff
May 23, 2016
Analysts and investors will be intently looking to see if the company meets or beats earnings projections after the next report. Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) is slated to next report quarterly earnings results on or around 2016-08-04. In the last report, the company announced EPS of $-0.35 against the Zacks Research consensus estimate of $0 for the period that ended on 2016-06-30. The gap between the estimate and actual was $-0.35 which created a surprise factor of N/A%. Big surprise factors may cause substantial moves in the stock price immediately after an earnings release, or in days and weeks that follow. As the earnings report date approaches, analysts may update models based on Street sentiment and company announcements. These can be key factors pointing to whether company earnings results will hit or miss consensus projections.
Mixing in prior earnings trends, future earnings projections and company issued and projected guidance, many Street analysts will also project future price target estimates. These reports are given to institutions to help educate and guide investment analysis. These reports may also be obtained by retail investors through different platforms. At the time of writing, the consensus target on shares of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) stands at $6.5. This is according to 2 sell-side analysts providing data polled by Zacks Research. The analyst with the most favorable view has the stock hitting $10, while the most conservative analyst has a target projection of $3 on the stock.
Going forward the Shorts are thinking maybe I better check the medicine cabinet and inventory the personal lubricant supply.
The pattern for several trading days since the exit of the former CEO has been to Open High and Close Low. I look for stabilization to occur with a day where the stock closes unchanged or up. Hopefully today is that day.
Analyst Comments, FDA
May 23, 2016 11:41 AM EDT
Lerink Partners analyst, Michael Schmidt, believes Cabo beating Sutent in the 1L RCC study is the best possible case scenario for Exelixis (NASDAQ: EXEL). The company announced positive "CABOSUN" Phase II top-line data" for EXEL's Cabometyx (Cabo) in first line renal cell carcinoma (RCC) this morning. The Outperform rating on shares of EXEL is based on the analyst's thesis that recently FDA approved Cabo is well positioned to capture significant market share in 2nd/3rd line treatment of RCC.
The approved Cabo data and label are impressive and the stock's current valuation only reflects a modest opportunity for the product in RCC. Today's news on Cabo further supports this theses. The positive Ph II results reported could justify potential NCCN listing (and hence reimbursed use) in treatment of intermediate/high risk 1L RCC and solidify Cabo as agent of choice in 2L and 3L even in a theoretical future scenario where more immuno-oncology (IO) agents are being used in 1L.
Cabo superior vs. Sutent in randomized Phase II trial in treatment- naïve advanced RCC patients. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Cabo compared with Sutent in patients with advanced intermediate- or poor-risk RCC. This represents the first time that an agent has shown superiority over Sutent in 1L RCC. Full results will be submitted for presentation at a future medical conference. The "CABOSUN" trial is part of EXEL's collaboration with the NCI (CTEP program).
The firm maintained an Outperform rating and price target of $8 on EXEL.
This dolt has posted every five minutes since the open and might have 100 message posts today.
Sunday, 15 May 2016 05:10 AM
Search for full article at Google by Headline
What we’re hoping is that CEO Sedor can build off the company’s foundation and continue expanding the Pernix Prescriptions Direct (PPD) program. As of Q1, over 10,000 patients have enrolled in the program since inception. PPD currently represents 11% of Treximet and 6% of Silenor weekly total prescriptions.
In terms of financial engineering, he needs to reduce interest expense and SG&A expenses. Selling, general and administrative expense (SG&A) in the first quarter 2016 increased by $5.5 million, or 27%, to $26.0 million as compared to $20.5 million in the first quarter of 2015. The increase was driven primarily by selling and marketing costs for Zohydro ER with BeadTek, which was acquired in April 2015. Interest expense for the three months ended March 31, 2016 was $9.0 million compared to $9.4 million last year. As of March 31, 2016, the company had total liquidity of $47.4 million, consisting of $36.6 million of cash and approximately $10.8 million available to draw under its $50.0 million revolving credit facility. Total principal amount of debt outstanding at the end of the quarter was $339.1 million and net debt was $302.5 million. The total principal amount of debt consists of $195.1 million of 12% Senior Secured notes, $130.0 million of 4.25% convertible notes and $14.0 million under its revolving credit facility. The company added:
Pernix continues to pursue a number of actions to improve its financial flexibility and strengthen its balance sheet. These actions include improving the Company’s operating cash flow generation by optimizing its product portfolio, continuing to examine its cost structure, engaging with lenders to constructively restructure existing debt and exploring strategic partnerships and collaborations. While Pernix is committed to actively pursuing these activities, there can be no assurance that these initiatives will result in any transacti
“Back up the truck, my friends.”